https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-kol-event-parp-inhibitors-oncology BiopharmaWatch en 2026-08-18T20:15:00.000Z Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald https://www.biopharmawatch.com/news/SILO/silo-pharma-canadian-patent-ptsd-treatment BiopharmaWatch en 2026-08-18T20:15:00.000Z Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment https://www.biopharmawatch.com/news/ONC/beone-medicines-extend-partnership-brukinsa-access BiopharmaWatch en 2026-08-18T20:09:00.000Z Samenvatting: BeOne Medicines, BeOne Care Foundation en The Max Foundation verlengen samenwerking om toegang tot BRUKINSA® voor de behandeling van chronische lymfatische leukemie in lage- en middeninkomenslanden te vergroten https://www.biopharmawatch.com/news/IRIX/iridex-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-18T20:05:00.000Z Iridex Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-350-million-offering BiopharmaWatch en 2026-08-18T20:01:00.000Z Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock https://www.biopharmawatch.com/news/HALO/halozyme-appoints-dannielle-appelhans-board-directors BiopharmaWatch en 2026-08-18T20:01:00.000Z Halozyme Appoints Dannielle Appelhans to its Board of Directors https://www.biopharmawatch.com/news/LIMN/liminatus-pharma-reverse-stock-split BiopharmaWatch en 2026-08-18T20:01:00.000Z Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock https://www.biopharmawatch.com/news/ONC/beone-medicines-renews-partnership-brukinsa-access BiopharmaWatch en 2026-08-18T19:56:00.000Z BeOne Medicines ومؤسسة BeOne Care Foundation ومؤسسة The Max Foundation تجدد شراكتها لتوسيع نطاق الوصول إلى BRUKINSA®‎ لعلاج سرطان الدم الليمفاوي المزمن في البلدان ذات الدخل المنخفض والمتوسط https://www.biopharmawatch.com/news/ONC/beone-medicines-renews-collaboration-brukinsa-access BiopharmaWatch en 2026-08-18T19:18:00.000Z Riassunto: BeOne Medicines, BeOne Care Foundation e The Max Foundation rinnovano la collaborazione per ampliare l'accesso a BRUKINSA® per il trattamento della leucemia linfatica cronica nei Paesi a reddito medio-basso https://www.biopharmawatch.com/news/BLLN/cfDNA-fetal-risk-assessment-general-risk-pregnancies BiopharmaWatch en 2026-08-18T16:08:00.000Z Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions https://www.biopharmawatch.com/news/ELUT/cellution-biologics-acquires-simpliderm-elutia BiopharmaWatch en 2026-08-18T15:19:00.000Z Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc. https://www.biopharmawatch.com/news/NTHI/neonc-technologies-insider-buying-and-clinical-success BiopharmaWatch en 2026-08-18T14:18:00.000Z NeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t https://www.biopharmawatch.com/news/CODX/co-diagnostics-medical-devices-innovation-roundtable BiopharmaWatch en 2026-08-18T13:30:00.000Z Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event https://www.biopharmawatch.com/news/DARE/dare-bioscience-ceo-forbes-50-over-50-innovation BiopharmaWatch en 2026-08-18T13:02:00.000Z DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List https://www.biopharmawatch.com/news/CON/concentra-appoints-dr-jill-rosenthal-cmo BiopharmaWatch en 2026-08-18T13:00:00.000Z Concentra Appoints Dr. Jill Rosenthal as Chief Medical Officer to Advance Clinical Innovation and Workforce Health https://www.biopharmawatch.com/news/UNH/unitedhealthcare-expands-behavioral-coaching-access BiopharmaWatch en 2026-08-18T13:00:00.000Z UnitedHealthcare Expands Access to Child and Family Behavioral Coaching to 13 Million Commercial Members https://www.biopharmawatch.com/news/GEHC/ge-healthcare-appoints-william-grogan-cfo BiopharmaWatch en 2026-08-18T13:00:00.000Z GE HealthCare appoints William Grogan as Chief Financial Officer https://www.biopharmawatch.com/news/DGX/whoop-advanced-labs-access-without-membership BiopharmaWatch en 2026-08-18T13:00:00.000Z WHOOP Makes Advanced Labs Available Without a Wearable Membership https://www.biopharmawatch.com/news/BAX/baxter-early-tender-results-upsizing-offers BiopharmaWatch en 2026-08-18T13:00:00.000Z Baxter Announces Early Tender Results and Upsizing of Previously Announced Cash Tender Offers https://www.biopharmawatch.com/news/PRVA/privia-health-appoints-opella-ernest-board-directors BiopharmaWatch en 2026-08-18T13:00:00.000Z Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors https://www.biopharmawatch.com/news/ONCY/oncolytics-fda-registrational-path-colorectal-cancer BiopharmaWatch en 2026-08-18T13:00:00.000Z Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer https://www.biopharmawatch.com/news/POCI/precision-optics-appoints-peter-thier-svp-sales-marketing BiopharmaWatch en 2026-08-18T13:00:00.000Z Precision Optics Appoints Peter Thier as Senior Vice President of Sales and Marketing https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-aktx-101-urothelial-cancer-data BiopharmaWatch en 2026-08-18T12:53:00.000Z Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-hc-wainwright-conference BiopharmaWatch en 2026-08-18T12:45:00.000Z Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/CDIO/cardio-diagnostics-in-house-lab-iowa-city BiopharmaWatch en 2026-08-18T12:35:00.000Z Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City https://www.biopharmawatch.com/news/QTI/qt-imaging-mid-year-2026-ceo-letter BiopharmaWatch en 2026-08-18T12:30:00.000Z QT Imaging Issues Mid-Year 2026 CEO Letter to Shareholders https://www.biopharmawatch.com/news/FBLG/fibrobiologics-chondrocyte-spheroids-cartilage-repair BiopharmaWatch en 2026-08-18T12:30:00.000Z FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-fda-fast-track-pln-101095 BiopharmaWatch en 2026-08-18T12:30:00.000Z Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-phase-1b-clinical-study-prp BiopharmaWatch en 2026-08-18T12:30:00.000Z Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP https://www.biopharmawatch.com/news/FEED/envue-medical-uroshield-distribution-agreement BiopharmaWatch en 2026-08-18T12:30:00.000Z ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million https://www.biopharmawatch.com/news/CNXU/conexeu-sciences-regenerative-aesthetics-market-growth BiopharmaWatch en 2026-08-18T12:30:00.000Z Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration https://www.biopharmawatch.com/news/RKTO/rocket-one-launches-drone-swarm-emulation-platform BiopharmaWatch en 2026-08-18T12:08:00.000Z Rocket One Launches Swarm Stage AI Drone-Swarm Threat Emulation Platform for U.S. Military Counter-UAS https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-financing-cad5-4-million BiopharmaWatch en 2026-08-18T12:06:00.000Z SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million https://www.biopharmawatch.com/news/HUMA/first-commercial-symvess-implantation-arizona BiopharmaWatch en 2026-08-18T12:00:00.000Z Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement” https://www.biopharmawatch.com/news/ENTX/entera-appoints-riccardo-paolo-camisasca-cmo BiopharmaWatch en 2026-08-18T12:00:00.000Z Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation https://www.biopharmawatch.com/news/BIAF/bioaffinity-avmedical-distribution-agreement-cypath-lung BiopharmaWatch en 2026-08-18T12:00:00.000Z bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung https://www.biopharmawatch.com/news/TRLV/trulieve-closing-bell-nyse-cannabis-company BiopharmaWatch en 2026-08-18T12:00:00.000Z Trulieve to Ring The Closing Bell at the New York Stock Exchange as First U.S. Cannabis Company Listed on the NYSE https://www.biopharmawatch.com/news/GRFS/kedrion-grifols-agreement-extension-gammaked BiopharmaWatch en 2026-08-18T12:00:00.000Z Kedrion Biopharma Announces the Extension of a U.S. Agreement with Grifols to Support Long-Term and Continued Access to GAMMAKED® https://www.biopharmawatch.com/news/ABBV/abbvie-immunology-scholarship-2026-recipients BiopharmaWatch en 2026-08-18T12:00:00.000Z AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-phase-1-2a-lithium-imaging-data-presentation BiopharmaWatch en 2026-08-18T12:00:00.000Z Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain https://www.biopharmawatch.com/news/ELUT/elutia-simpliderm-sale-nxt-41x-launch BiopharmaWatch en 2026-08-18T12:00:00.000Z Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch https://www.biopharmawatch.com/news/RCEL/avitamedical-permeaderm-study-results-economic-advantage BiopharmaWatch en 2026-08-18T11:45:00.000Z AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes https://www.biopharmawatch.com/news/HELP/helus-pharma-appoints-regina-donohue-suresh-durgam BiopharmaWatch en 2026-08-18T11:30:32.000Z Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board https://www.biopharmawatch.com/news/AMLX/amylyx-phase-3-lucidity-trial-avexitide-results BiopharmaWatch en 2026-08-18T11:00:00.000Z Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia https://www.biopharmawatch.com/news/LH/labcorp-nachc-strategic-alliance-community-health BiopharmaWatch en 2026-08-18T11:00:00.000Z Labcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community Health https://www.biopharmawatch.com/news/GNPX/genprex-manufacturing-scale-up-diabetes-gene-therapy BiopharmaWatch en 2026-08-18T11:00:00.000Z Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy https://www.biopharmawatch.com/news/BLSM/blossomhill-fda-fast-track-bh-30643 BiopharmaWatch en 2026-08-18T11:00:00.000Z BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC https://www.biopharmawatch.com/news/IMTX/immatics-q2-2026-financial-results-business-update BiopharmaWatch en 2026-08-18T11:00:00.000Z Immatics Announces Second Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/PFE/pfizer-settlement-depo-provera-litigation BiopharmaWatch en 2026-08-18T10:15:00.000Z Legal Bay Pre-Settlement Funding Reports Pfizer Agrees to Settle Depo-Provera Birth Control Litigation https://www.biopharmawatch.com/news/ONC/beone-medicines-renews-partnership-brukinsa-access BiopharmaWatch en 2026-08-18T10:00:00.000Z BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries https://www.biopharmawatch.com/news/NUTX/nutex-health-opens-west-little-rock-emergency-hospital BiopharmaWatch en 2026-08-18T09:30:00.000Z NUTEX HEALTH OPENS WEST LITTLE ROCK EMERGENCY HOSPITAL IN ARKANSAS https://www.biopharmawatch.com/news/SNN/smith-nephew-imperial-college-robotic-surgery-innovation BiopharmaWatch en 2026-08-18T07:01:00.000Z Smith+Nephew and Imperial College London launch centre to accelerate innovation in surgical robotics https://www.biopharmawatch.com/news/CHRS/coherus-oncology-special-dividend-cvr BiopharmaWatch en 2026-08-17T21:33:00.000Z Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights https://www.biopharmawatch.com/news/BDX/bd-appoints-gary-sorsher-chief-quality-officer BiopharmaWatch en 2026-08-17T20:30:00.000Z BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-inducement-grant-nasdaq-rule-5635c4 BiopharmaWatch en 2026-08-17T20:28:00.000Z Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/DCGO/docgo-announces-q2-2026-results BiopharmaWatch en 2026-08-17T20:20:00.000Z DocGo Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/IQV/iqvia-ranked-no-1-pharmaceutical-technology-provider BiopharmaWatch en 2026-08-17T20:15:00.000Z IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group https://www.biopharmawatch.com/news/CVS/cvs-health-board-changes-2026 BiopharmaWatch en 2026-08-17T20:15:00.000Z CVS Health Announces Board Changes https://www.biopharmawatch.com/news/POCI/precision-optics-lytham-partners-summit-2026 BiopharmaWatch en 2026-08-17T20:15:00.000Z Precision Optics to Participate in the Lytham Partners 2026 Consumer & Technology Investor Summit on August 18, 2026 https://www.biopharmawatch.com/news/RMD/resmed-appoints-carol-burt-lead-director BiopharmaWatch en 2026-08-17T20:10:00.000Z Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor https://www.biopharmawatch.com/news/AMLX/amylyx-announces-topline-results-phase-3-lucidity-trial BiopharmaWatch en 2026-08-17T20:01:00.000Z Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026 https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-public-offering-closure BiopharmaWatch en 2026-08-17T20:01:00.000Z Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares https://www.biopharmawatch.com/news/MOH/molina-donates-food-kitchen-saginaw BiopharmaWatch en 2026-08-17T19:00:00.000Z The MolinaCares Accord and Molina Healthcare of Michigan Donate $100,000 to Support Construction of a New Food Kitchen in Saginaw County https://www.biopharmawatch.com/news/VOGX/vogenx-ipo-813-million-jones-trading BiopharmaWatch en 2026-08-17T16:25:00.000Z Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering https://www.biopharmawatch.com/news/SYK/stryker-joint-replacement-caregivers-bmw-championship BiopharmaWatch en 2026-08-17T15:19:00.000Z Stryker spotlights the joint replacement journey and the vital role of caregivers at the 2026 BMW Championship https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-appoints-carol-brosgart BiopharmaWatch en 2026-08-17T15:17:00.000Z Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors https://www.biopharmawatch.com/news/INCY/global-vitiligo-foundation-supports-incyte-campaign BiopharmaWatch en 2026-08-17T15:14:00.000Z Global Vitiligo Foundation Applauds Incyte’s “Moments of Clarity” Campaign for Elevating Patient Voices and Advancing Vitiligo Awareness https://www.biopharmawatch.com/news/CRBP/corbus-inducement-grants-leonardo-nicacio BiopharmaWatch en 2026-08-17T14:00:00.000Z Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ARWR/redeemplo-available-fcs-patients-germany BiopharmaWatch en 2026-08-17T13:33:00.000Z People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides https://www.biopharmawatch.com/news/MMED/minimed-flex-insulin-pump-shipping BiopharmaWatch en 2026-08-17T13:04:00.000Z MiniMed's Smallest App-Controlled Insulin Pump Now Shipping with the World's Smallest Sensor https://www.biopharmawatch.com/news/PLUR/pluri-ever-after-foods-fishway-acquisition-investment BiopharmaWatch en 2026-08-17T13:00:00.000Z Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment https://www.biopharmawatch.com/news/IGC/igc-pharma-q2-2026-results-calma-trial-update BiopharmaWatch en 2026-08-17T12:55:48.000Z IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer’s Trial Moves Within Six Randomizations of Enrollment Closure https://www.biopharmawatch.com/news/UHS/universal-health-services-acquires-talkspace BiopharmaWatch en 2026-08-17T12:52:00.000Z Universal Health Services, Inc. Completes Acquisition of Talkspace, Inc. https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-notice-allowance-art27-13 BiopharmaWatch en 2026-08-17T12:52:00.000Z Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies https://www.biopharmawatch.com/news/NTHI/nthi-nasdaq-advantage-phase-2a-results BiopharmaWatch en 2026-08-17T12:45:00.000Z NTHI’s Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results https://www.biopharmawatch.com/news/AIDX/2020-biolabs-q2-2026-financial-results BiopharmaWatch en 2026-08-17T12:31:00.000Z 20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-private-placement-nasdaq BiopharmaWatch en 2026-08-17T12:30:00.000Z Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/CVM/cel-sci-reports-fiscal-third-quarter-2026-results BiopharmaWatch en 2026-08-17T12:30:00.000Z CEL-SCI Reports Fiscal Third Quarter 2026 Results https://www.biopharmawatch.com/news/IVF/invo-fertility-q2-2026-results-revenue-growth BiopharmaWatch en 2026-08-17T12:30:00.000Z INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability https://www.biopharmawatch.com/news/TRIB/trinity-biotech-trinovium-echelon-cooling-solutions BiopharmaWatch en 2026-08-17T12:30:00.000Z Trinity Biotech’s Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI Infrastructure https://www.biopharmawatch.com/news/DWTX/dogwood-virtual-kol-event-halneuron-cinp BiopharmaWatch en 2026-08-17T12:30:00.000Z Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026 https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-iso-recertification BiopharmaWatch en 2026-08-17T12:30:00.000Z Intelligent Bio Solutions Strengthens Quality Management Credentials with ISO Recertification https://www.biopharmawatch.com/news/NSRX/nasus-pharma-h1-2026-financial-results-update BiopharmaWatch en 2026-08-17T12:14:00.000Z Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ACXP/acurx-fda-conditional-acceptance-ibezapolstat BiopharmaWatch en 2026-08-17T12:01:00.000Z Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat https://www.biopharmawatch.com/news/URGN/urogen-submits-nda-ugn-103-recurrent-lg-ir-nmibc BiopharmaWatch en 2026-08-17T12:00:00.000Z UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC https://www.biopharmawatch.com/news/NDRA/endra-life-sciences-q2-2026-financial-results BiopharmaWatch en 2026-08-17T12:00:00.000Z ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CON/concentra-strengthens-workforce-health-access-minnesota-acquisition BiopharmaWatch en 2026-08-17T12:00:00.000Z Concentra Strengthens Workforce Health Access in Minnesota Through Acquisition https://www.biopharmawatch.com/news/SVA/sinovac-reports-first-half-2026-financial-results BiopharmaWatch en 2026-08-17T12:00:00.000Z SINOVAC Reports Unaudited First Half of 2026 Financial Results https://www.biopharmawatch.com/news/GCTK/glucotrack-compliance-milestone-strategic-transformation BiopharmaWatch en 2026-08-17T12:00:00.000Z Glucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation https://www.biopharmawatch.com/news/BHC/bausch-health-gastrointestinal-health-scholars-2026 BiopharmaWatch en 2026-08-17T12:00:00.000Z Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners https://www.biopharmawatch.com/news/LH/labcorp-investor-day-september-2026 BiopharmaWatch en 2026-08-17T12:00:00.000Z Labcorp to Host Investor Day on September 10, 2026 https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-baird-2026-healthcare-conference BiopharmaWatch en 2026-08-17T12:00:00.000Z PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026 https://www.biopharmawatch.com/news/NXGL/nexgel-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-17T12:00:00.000Z NEXGEL Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-appoints-aj-joshi-cmo BiopharmaWatch en 2026-08-17T12:00:00.000Z Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer https://www.biopharmawatch.com/news/AVXL/anavex-director-nominees-annual-meeting-2026 BiopharmaWatch en 2026-08-17T12:00:00.000Z Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees https://www.biopharmawatch.com/news/SNN/smith-nephew-flow-flextend-coblation-wand-launch BiopharmaWatch en 2026-08-17T12:00:00.000Z Smith+Nephew’s new FLOW FLEXTEND™ COBLATION™ Wand improves access¹* and resection efficiency²** for complex hip procedures vs. fixed-angle options https://www.biopharmawatch.com/news/EVAX/evaxion-expands-rd-pipeline-evx-05-brain-cancer-vaccine BiopharmaWatch en 2026-08-17T12:00:00.000Z Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program https://www.biopharmawatch.com/news/OSTX/os-therapies-q2-2026-financials-regulatory-updates BiopharmaWatch en 2026-08-17T11:40:00.000Z OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-fda-fast-track-piktor-paclitaxel BiopharmaWatch en 2026-08-17T11:30:00.000Z Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer https://www.biopharmawatch.com/news/CGC/canopy-growth-mailing-proxy-materials-2026-meeting BiopharmaWatch en 2026-08-17T11:30:00.000Z Canopy Growth Announces Mailing of Proxy Materials for 2026 Annual General and Special Meeting – Urges Shareholders to Vote Now https://www.biopharmawatch.com/news/RADX/radiopharm-fda-meeting-phase-3-trial-design-rad101 BiopharmaWatch en 2026-08-17T11:30:00.000Z Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases https://www.biopharmawatch.com/news/CANF/can-fite-namodenoson-enhances-chemotherapy-pancreatic-cancer BiopharmaWatch en 2026-08-17T11:00:00.000Z Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer https://www.biopharmawatch.com/news/UTHR/united-therapeutics-teton-ppf-study-enrollment BiopharmaWatch en 2026-08-17T11:00:00.000Z United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis https://www.biopharmawatch.com/news/PLSM/pulsenmore-ai-grant-smartscan-program BiopharmaWatch en 2026-08-17T11:00:00.000Z Pulsenmore Receives Second AI Grant Within One Month: Israel Innovation Authority Approves $1.27 Million for SmartScan AI Program https://www.biopharmawatch.com/news/CSTL/castle-biosciences-dual-listing-nasdaq-texas BiopharmaWatch en 2026-08-17T11:00:00.000Z Castle Biosciences Approved for Dual Listing on Nasdaq Texas https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-17T11:00:00.000Z InspireMD Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/EYPT/eyepoint-lugano-phase-3-results-duravyu-wet-amd BiopharmaWatch en 2026-08-17T11:00:00.000Z EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-q2-2026-financial-results-update BiopharmaWatch en 2026-08-17T11:00:00.000Z NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET https://www.biopharmawatch.com/news/FULC/fulcrum-slate-merger-next-gen-migraine-therapies BiopharmaWatch en 2026-08-17T11:00:00.000Z Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies https://www.biopharmawatch.com/news/KMDA/kamada-cash-dividend-record-high-revenue-2026 BiopharmaWatch en 2026-08-17T11:00:00.000Z Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026 https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-q2-2026-financial-results-update BiopharmaWatch en 2026-08-17T11:00:00.000Z Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update https://www.biopharmawatch.com/news/IMCC/im-cannabis-agreement-sell-imc-holdings-assets BiopharmaWatch en 2026-08-17T10:32:00.000Z IM Cannabis Enters into Agreement to Sell IMC Holdings and European- Focused Assets https://www.biopharmawatch.com/news/ACH/accendra-health-capital-allocation-ceo-succession BiopharmaWatch en 2026-08-17T10:30:00.000Z Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans https://www.biopharmawatch.com/news/OABI/omniab-raises-2026-financial-guidance BiopharmaWatch en 2026-08-17T10:06:00.000Z OmniAb Raises 2026 Financial Guidance https://www.biopharmawatch.com/news/OABI/omniab-global-collaboration-eli-lilly-ion-channel BiopharmaWatch en 2026-08-17T10:01:00.000Z OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company https://www.biopharmawatch.com/news/ZLAB/zai-lab-argenx-positive-results-efgartigimod-trial BiopharmaWatch en 2026-08-17T10:00:00.000Z Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-08-17 BiopharmaWatch en 2026-08-17T07:15:41.150Z Biotech Catalysts to Watch: Key Developments Ahead for TENX and SION https://www.biopharmawatch.com/news/ARGX/argenx-positive-results-phase-3-alkivia-trial BiopharmaWatch en 2026-08-17T05:00:00.000Z argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis https://www.biopharmawatch.com/news/MESO/mesoblast-completes-patient-treatment-phase-3-trial BiopharmaWatch en 2026-08-17T00:35:00.000Z Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain https://www.biopharmawatch.com/news/GLMD/galmed-arachmol-enzalutamide-prostate-cancer-results BiopharmaWatch en 2026-08-17T00:00:00.000Z Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models Xtandi® (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of...